SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1,… Read More: High-cost Gilead cell therapy proves durable for some lymphoma patients »
When you think of menopause, you might think of hot flashes and night sweats. But many women also experience symptoms of depression. The risk of depression doubles or even quadruples during the menopausal transition, which has researchers looking for ways to address — or even prevent — the problem. One study published in JAMA Psychiatry… Read More: Hormone therapy for depression: Are the risks worth the benefits? »
November 09, 2018 Share this content: Chloride sweat concentrations and Cystic Fibrosis Questionnaire-Revised scores improved when VX-659 was added to tezacaftor and ivacaftor. Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and ivacaftor showed improved forced expiratory volume in 1 second (FEV1),… Read More: Cystic Fibrosis Lung Function Improved With Triple Therapy »
Due to the rapidly growing needs in the medical and healthcare industries – particularly in different metropolitan areas – physical therapists have been in high demand. Having an aging population that continues to undergo longer life expectancy, as well as continued advancements in these sorts of remedies, licensed professionals with physical therapy training not only… Read More: Best Physical Therapy Training Leads To The Best PT Careers »